AARD

Business Context and Reporting Period

Aardvark Therapeutics, Inc. (AARD) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for metabolic diseases, specifically targeting hunger-associated conditions via Bitter Taste Receptors (TAS2Rs). The company completed its Initial Public Offering (IPO) in February 2025. This filing covers the quarterly period ended September 30, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Surge: Operating expenses increased significantly, driven by the advancement of clinical trials. Research and Development (R&D) expenses rose to $13.7 million in Q3 2025 from $4.1 million in Q3 2024. General and Administrative (G&A) expenses increased to $4.0 million from $1.0 million, reflecting costs associated with becoming a public company.
• Capital Structure: In February 2025, the company completed its IPO, raising approximately $87.5 million in net proceeds. All outstanding convertible preferred stock was converted into common stock.
• Investment Portfolio: Short-term investments increased substantially to $87.1 million as of September 30, 2025, compared to $12.0 million at year-end 2024, following the IPO proceeds.
• Related Party Write-offs: The company wrote off $0.1 million in credit losses related to a related party (Aardwolf Therapeutics) in the prior year period; no such losses were recorded in the current period as the receivables were previously deemed uncollectible.

Guidance, Outlook, and Risks

• Clinical Pipeline:
  • ARD-101: The company is conducting the Phase 3 HERO trial for hyperphagia associated with Prader-Willi Syndrome (PWS). Enrollment began in Q2 2025. Topline data is expected in Q3 2026. The company recently aligned with the FDA to lower the minimum age eligibility from 13 to 10 years.
  • ARD-201: Plans to evaluate ARD-101 for hypothalamic obesity (HONOR trial) were delayed indefinitely to focus resources on ARD-201 (a combination of ARD-101 and a DPP-4 inhibitor). Two new Phase 2 trials, POWER and STRENGTH, are planned to explore weight regain prevention and weight reduction.
• Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments of $126.4 million are sufficient to fund operations into 2027. However, the company expects to incur substantial additional losses and will require further capital to complete development and commercialization.
• Material Weakness: The company identified a material weakness in internal controls over financial reporting related to a lack of segregation of duties and insufficient qualified resources. A remediation plan is underway, including hiring additional personnel and implementing a new ERP system.
• Risks: Key risks include the failure of clinical trials, inability to secure additional funding, regulatory delays (including potential government shutdown impacts), and competition in the obesity and metabolic disease space.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $126.4 million liquidity position against the accelerating burn rate (approx. $16.3 million net loss in Q3 alone).
• Internal Controls: Monitor the progress of the remediation plan for the material weakness in financial reporting to ensure future financial accuracy.
• Clinical Milestones: Track enrollment progress in the Phase 3 HERO trial and the timeline for the interim analysis and topline data (expected Q3 2026).
• Related Party Exposure: Confirm the status of the $1.4 million unreimbursed costs and $1.0 million note receivable from Aardwolf Therapeutics, which are currently written off but subject to reassessment.
• Regulatory Alignment: Verify the impact of the FDA protocol amendment lowering the age eligibility for the HERO trial on the total addressable market.